Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy

US6506572B2 · kind B2 · utility

Assignee

• Klinge Pharma GmbH · DE

Inventors

• Elfi Biedermann · Vaterstetten, DE
• Rolf Eisenburger · Kirchseeon, DE
• Max Hasmann · Schwanau, DE
• Roland Loser · Feldafing, DE
• Benno Rattel · Munich, DE
• Friedemann Reiter · Putzbrunn, DE
• Barbara Schein · Neufahrn, DE
• Isabel Schemainda · Munich, DE
• Michael Schulz · Ludwigshafen, DE
• Klaus Seibel · Gräfelfing, DE
• Klaus Vogt · Munich, DE
• Katja Wosikowski · Poing, DE

Key dates

• Filing date: Aug 23, 2001
• Grant date: Jan 14, 2003
• Expiry date: Aug 23, 2021

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/5038
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.